NCT06544434

Brief Summary

Objective: To evaluate the effect of laser acupuncture for the patients Meniere disease. Methods: We enrolled 324 patients at Beijing Tongren Hospital. Patients completed outcome measures at baseline, 3 months, 6 months, and 12 months. Video head impulse test (vHIT), The Caloric Test, Tinnitus Handicap Inventory (THI), Dizziness Handicap Inventory (DHI), Pure Tone Audiometry (PTA), and visual scale of ear stuffiness to evaluate the therapeutic effects. A difference of P \< 0.05 was considered statistically significant.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
324

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started May 2021

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2021

Completed
3.3 years until next milestone

First Submitted

Initial submission to the registry

August 6, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 9, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
20 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 20, 2024

Completed
Last Updated

August 9, 2024

Status Verified

July 1, 2024

Enrollment Period

3.4 years

First QC Date

August 6, 2024

Last Update Submit

August 6, 2024

Conditions

Keywords

Meniere DiseaseRCTLaser acupuncture

Outcome Measures

Primary Outcomes (4)

  • Dizziness Handicap Inventory (DHI)

    The DHI is 25-items self-reported questionnaire that used to evaluate the functional, emotional, and physical impact of dizziness on patients' daily life. Among the overall 25 items of questions, 9 items are emotional related, 9 items are functional related, and 7 items are physical related questions. The three answer options are "yes," "sometimes," and "no," with scores of 4, 2, and 0, respectively. The overall score is the sum of 25 items (Range: 0-100). Higher scores equate to greater severity of dizziness symptoms.

    Baseline, month 3, 6 and 12

  • Tinnitus Handicap Inventory (THI)

    The THI is a 25-items, self-reported questionnaire regarding tinnitus handicap in daily life. The questionnaire comprises a 12-item functional subscale, an 8-item emotional subscale, and a 5-item catastrophic subscale. The three answer options are "yes," "sometimes," and "no," with scores of 4, 2, and 0, respectively. The overall score is the sum of 25 items (Range: 0-100). Higher scores equate to greater severity of tinnitus symptoms.

    Baseline, month 3, 6 and 12

  • Pure tone thresholds (PTA)

    The pure tone thresholds was performed in a sound-attenuated, double-walled booth with circumaural headphones (Sennheiser HD 280 for frequencies from 250 to 8000 Hz and Sennheiser HD 200 for frequencies from 8000 to 14000 Hz; Sennheiser, Old Lyme, USA) on a certified and calibrated audiometric system (Interacoustics, Middelfart, Denmark). Thresholds were measured using a probe-detection paradigm with pure tones presented for 250 ms at frequencies of 250, 500, 1000, 2000, 4000, 8000 Hz for each ear. To determine the LDL, the volume was set to 75 dB at 1000 Hz and then continuously raised in 5 dB steps (every 5 s) until the subject gave the signal that this volume was uncomfortable. When the volume exceeded 110 dB the test was stopped to prevent any hearing damage. The severity of hearing impairment was calculated as mild (20-40 dB), moderate (41-70 dB), severe (71-95 dB) and profound (\>95 dB). Normal hearing was defined as pure-tone thresholds less than 20 dB.

    Baseline, month 3, 6 and 12

  • Visual analogue scale (VAS)

    The VAS scale of aural fullness consists of a 100 mm straight line with defined endpoints ("no aural fullness" and "worst aural fullness imaginable") on which the patients were asked to mark their experienced aural fullness (results in mm) at the actual time ("VAS now"). The higher VAS score (Range: 0-100) is correlated with a severe aural fullness.

    Baseline, month 3, 6 and 12

Secondary Outcomes (2)

  • Video head impulse test (vHIT)

    Baseline, month 3, 6 and 12

  • The Caloric Test

    Baseline, month 3, 6 and 12

Study Arms (3)

Laser acupuncture 3 month Group

EXPERIMENTAL
Device: Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy)Drug: Betahistine Mesylate tablet

Sham acupuncture Group

SHAM COMPARATOR
Device: Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy)Drug: Betahistine Mesylate tablet

Control Group

OTHER
Drug: Betahistine Mesylate tablet

Interventions

MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.

Laser acupuncture 3 month GroupSham acupuncture Group

Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.

Control GroupLaser acupuncture 3 month GroupSham acupuncture Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of meniere disease.

You may not qualify if:

  • Serious mental illness or social problems, and neurological disorders, and systemic diseases, such as malignant tumors, and other serious consumptive diseases.
  • Planning for pregnancy, those in pregnancy, or those who were lactating.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing TongRen Hospital, Capital Medical University

Beijing, China

RECRUITING

MeSH Terms

Conditions

Meniere Disease

Interventions

LasersBetahistine

Condition Hierarchy (Ancestors)

Endolymphatic HydropsLabyrinth DiseasesEar DiseasesOtorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Optical DevicesEquipment and SuppliesRadiation Equipment and SuppliesPyridinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Haihong Lian, Doctor

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 6, 2024

First Posted

August 9, 2024

Study Start

May 1, 2021

Primary Completion

September 30, 2024

Study Completion

October 20, 2024

Last Updated

August 9, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
From the study publication to 5 years
Access Criteria
email

Locations